Abstract: A process for preparing an olefin stream for oligomerization comprises fractionating an olefin stream to provide a light gas stream and a olefin rich stream. Oxygenates are absorbed from the olefin rich stream into a water wash stream to provide an oxygenate rich water wash stream and a washed olefin stream. Oxygenates are then adsorbed from the washed olefin rich stream, so the deoxygenated stream can then be oligomerized.

Abstract: A process for preparing an olefin stream for oligomerization comprises fractionating an olefin stream to provide an ethylene stream and a olefin rich stream. Acetylenes in the ethylene stream are converted to ethylene in the presence of hydrogen to provide a concentrated ethylene stream that can be oligomerized.

Abstract: A process is provided for preparing a hydrocarbon stream for oligomerization. The process strips dimethyl ether from an olefin stream using a stripping column. Lighter olefins such as C3? olefins are also removed. The C4+ olefins can then be sent for further processing including selective hydrogenation followed by oligomerization.

Abstract: A process for preparing an olefin stream for oligomerization comprises fractionating an olefin stream to provide a light gas stream and an olefin rich stream. Oxygenates are absorbed from the olefin rich stream into a water wash stream to provide an oxygenate rich water wash stream and a washed olefin stream. The washed olefin stream can then be oligomerized.

Abstract: A process for preparing an olefin stream for oligomerization comprises fractionating an olefin stream to provide a light gas stream and a olefin rich stream. The olefin rich stream is selectively hydrogenated to convert diolefins to mono-olefins and provide a mono-olefin stream and oligomerizing the mono-olefin stream over an oligomerization catalyst to provide an oligomerized stream.

Abstract: The present disclosure includes substituted 1-aryl-1?-heteroaryl compounds, substituted 1,1?-biheteroaryl compounds, analogues thereof, and compositions comprising the same. Such compounds and analogues comprises compounds of formula (I). In one aspect, the compounds contemplated in the disclosure can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the disclosure can be used to treat, ameliorate, and/or prevent cancer in a patient.

Abstract: The present invention includes substituted tricyclic amides of formula (I), or a salt, solvate, prodrug, stereoisomer, tautomer, or isotopically labelled derivative thereof, or any mixtures thereof, and compositions comprising the same.

Abstract: The present disclosure includes certain substituted (phthalazin-1-ylmethyl)ureas, N-(phthalazin-1-ylmethyl)amides, and analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

Abstract: The present disclosure includes substituted isoquinolinylmethyl amides, or analogues thereof, and compositions comprising the same, that can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

Abstract: The present invention includes substituted 1,1?-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

Abstract: The present disclosure includes in one aspect substituted arylmethyl ureas, substituted heteroarylmethyl ureas, or analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

Abstract: The present disclosure includes novel substituted cyclopropyl-2,2?-bipyrimidinyl compounds, and compositions comprising the same. In certain embodiments, the compounds of the disclosure can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.

Abstract: The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat and/or prevent hepatitis B virus (HBV) infections in a patient.

Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.

Abstract: The present disclosure includes substituted isoindolinyl 2,2?-bipyrimidinyl compounds, analogues thereof, and compositions comprising the same, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis B virus (HBV)-hepatitis D virus (HDV) infection in a patient.

Abstract: The present invention includes substituted polycyclic carboxylic acids, analogues thereof, and compositions comprising the same, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) in a patient.

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

Abstract: The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.